Related Experiment Video
Updated: Aug 28, 2025
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Tepotinib: Management of Adverse Events in Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer
Linda Ahn1, Terri Alexander2, Soetkin Vlassak3
1Memorial Sloan Kettering Cancer Center.
Background:
Tepotinib, a highly selective, oral, once-daily MET inhibitor, has been approved for treatment of metastatic MET exon 14 skipping non-small cell lung cancer.
Objectives:
This article provides nurse-specific recommendations for identification and management of tepotinib adverse events (AEs).
Methods:
Guidance on monitoring and proactive/reactive AE management was developed based on published literature and real-world nursing experience. Case studies of VISION trial participants were summarized to illustrate key principles.
Findings:
Tepotinib AEs are generally mild to moderate and manageable, and can include peripheral edema, hypoalbuminemia, nausea, diarrhea, and creatinine increase. Alongside supportive care, tepotinib interruption and dose reduction is recommended for grade 3 AEs. For peripheral edema, proactive monitoring is crucial, and treatment interruption (including frequent, short treatment holidays) should be considered early. Nursing management of tepotinib AEs includes proactive monitoring, patient education, and interprofessional team coordination.
Insights
Tepotinib adverse events (AEs) in non-small cell lung cancer are manageable with nursing guidance. Recommendations focus on proactive monitoring and patient education for effective treatment.
Area of Science:
- Oncology
- Pharmacology
- Nursing Practice
Background:
- Tepotinib is an approved oral MET inhibitor for metastatic MET exon 14 skipping non-small cell lung cancer.
- Effective management of treatment-related adverse events (AEs) is crucial for patient outcomes.
Purpose of the Study:
- To provide nurse-specific recommendations for identifying and managing tepotinib-related AEs.
- To support healthcare professionals in optimizing patient care during tepotinib therapy.
Main Methods:
- Development of guidance based on published literature and real-world nursing experience.
- Summarization of case studies from the VISION trial to illustrate key management principles.
Main Results:
- Tepotinib AEs are typically mild to moderate, including peripheral edema, hypoalbuminemia, nausea, diarrhea, and creatinine increase.
- Management strategies involve supportive care, potential tepotinib interruption or dose reduction for severe AEs, and proactive monitoring for peripheral edema.
- Nursing management emphasizes proactive monitoring, patient education, and interprofessional collaboration.
Conclusions:
- Tepotinib AEs are generally manageable with appropriate nursing interventions.
- Proactive monitoring, patient education, and coordinated care are essential for safe and effective tepotinib use in non-small cell lung cancer.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...